Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9149

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Bipolar Disorder I or II With a Major Depressive Episode
Interventions: ALTO-100, Placebo; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 58
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 48 more

Conditions: Major Depressive Disorder
Interventions: Azetukalner; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 69
States / cities: Phoenix, Arizona • Bryant, Arkansas • Little Rock, Arkansas + 58 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: COYA 302, Placebo; Drug
Lead sponsor: Coya Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Weight Management
Interventions: Elecoglipron, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 56
States / cities: Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 53 more

Conditions: Secondary Progressive Multiple Sclerosis (SPMS)
Interventions: Remibrutinib (blinded), Placebo, Remibrutinib (Open label); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more

Conditions: Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Interventions: Axoguard HA+ Nerve Protector™; Device
Lead sponsor: Axogen Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: Tampa, Florida • Savannah, Georgia • Indianapolis, Indiana + 4 more

Conditions: Heart Failure and Impaired Kidney Function
Interventions: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, dapagliflozin 10 mg and matching placebo for balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 3,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 166
States / cities: Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 142 more

Conditions: Prurigo Nodularis
Interventions: Dupilumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 15
States / cities: Palo Alto, California • Rancho Santa Margarita, California • Walnut Creek, California + 12 more

Conditions: Endometrial Cancer
Interventions: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 62
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 56 more

Conditions: Early-Stage Non-Small Cell Lung Cancer
Interventions: Pumitamig, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 9
States / cities: Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more

Conditions: Eosinophilic Esophagitis
Interventions: Vonoprazan, Placebo; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 41
States / cities: Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more

Conditions: Weight Regain, Weight Loss
Interventions: TORe with OverStitch, Intensive lifestyle modification; Device · Behavioral
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Irvine, California • Stanford, California • Jacksonville, Florida + 8 more

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

ALTO-100 in Bipolar Disorder With Depression (BD-D)

An Open-Label Study of Azetukalner in Major Depressive Disorder

Study of COYA 302 for the Treatment of ALS

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass